Generation and characterization of single-chain antibody fragments specific against transmembrane envelope glycoprotein gp46 of maedi-visna virus

A single-chain antibody fragments (scFv) was developed directed against transmembrane envelope glycoprotein gp46 of the virus maedi-visna, by the application of the antibody phage display library. To get specific scFv binders, the library was panned against the biotinylated peptide of 20 amino acids corresponding to the principal immunodominant domain of gp46 protein. The number of positively binding scFvs was evaluated by scFv-phage ELISA, BstN1 fingerprinting and DNA sequencing. The scFvs were expressed in soluble form and purified by immobilized metal affinity chromatography (IMAC) with a yield of 2-2.5 mg/l. Two scFvs have shown to recognize gp46 and gp150 proteins in Western blot analysis. The scFvs also recognized the virus in infected cells as shown by immunofluorescence assay. The affinity of the obtained antibody fragments to gp46 peptide was measured by surface plasmon resonance, and the resulting K(A) was in the 10(6)-10(7)lmol(-1) range. The application of characterized scFvs for expression as intrabodies in intracellular immunization against virus maedi-visna infection and for the diagnosis of this virus is discussed.     

A virulent isolate of yellow head nidovirus contains a deformed envelope glycoprotein gp116

Yellow head virus (YHV) is a highly virulent pathogen of penaeid shrimp. An isolate obtained from Penaeus vannamei during a yellow head disease outbreak in February 2006 in Ratchaburi Province, Thailand was purified following passage in experimentally infected shrimp. SDS-PAGE of purified virions indicated that envelope glycoprotein gp116 in the Ratchaburi/2006 isolate was smaller and relatively less abundant than in the Chachoengsao/1998 YHV reference strain. The variant gp116 reacted poorly in immunoblots with a gp116 mouse monoclonal antibody and a rabbit anti-serum to a baculovirus-expressed, C-terminally truncated, [His]₆-tagged gp116 that reacted strongly with gp116 of the homologous Chachoengsao/1998 strain. The anti-gp116 polyclonal serum also failed to neutralise the infectivity of the Ratchaburi/2006 isolate in in-vivo assays conducted in P. vannamei, but effectively neutralised the infectivity of the reference strain. Sequence analysis of the ∼ 6.0 kb structural protein gene region and 3′UTR of the Ratchaburi/2006 isolate indicated > 99.9% overall nucleotide identity with the Chachoengsao/1998 strain. However, in Ratchaburi/2006 a deletion in ORF3, corresponding to 54 amino acids near the N-terminal signal peptidase cleavage site of gp116, resulted in the loss of six conserved cysteine residues and two predicted N-glycosylation sites. Analysis of this ORF3 region in 25 viruses representing each of the six genotypes in the yellow head complex identified this modified form of gp116 in two other virulent YHV isolates classified as genotype 1b. The data indicate that, although the deletion causes a significant structural deformation of gp116 which reduces its incorporation into virions and eliminates the major neutralisation sites, the virus remains highly infectious, virulent and fit for survival.     

Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency

Human and equine rabies immunoglobulins are currently available for passive immunization against rabies. However, these are hampered by the limited supply and some drawbacks. Advances in antibody engineering have led to overcome issues of clinical applications and to improve the protective efficacy. In the present study, we report the generation of a trivalent single-chain Fv (scFv50AD1-Fd), that recognizes the rabies virus glycoprotein, genetically fused to the trimerization domain of the bacteriophage T4 fibritin, termed ‘foldon’ (Fd). scFv50AD1-Fd was expressed as soluble recombinant protein in bacterial periplasmic space and purified through affinity chromatography. The molecular integrity and stability were analyzed by polyacrylamide gradient-gel electrophoresis, size-exclusion chromatography and incubation in human sera. The antigen-binding properties of the trimeric scFv were analyzed by direct and competitive-ELISA. Its apparent affinity constant was estimated at 1.4 ± 0.25 × 10⁹ M⁻¹ and was 75-fold higher than its monovalent scFv (1.9 ± 0.68 × 10⁷ M⁻¹). The scFv50AD1-Fd neutralized rabies virus in a standard in vitro and in vivo neutralization assay. We showed a high neutralization activity up to 75-fold compared with monovalent format and the WHO standard serum. The gain in avidity resulting from multivalency along with an improved biological activity makes the trivalent scFv50AD1-Fd construct an important reagent for rabies protection. The antibody engineering approach presented here may serve as a strategy for designing a new generation of anti-rabies for passive immunotherapy.     

Chicken single-chain antibody fragments directed against recombinant VP7 of bluetongue virus

VP7, the major structural core protein of bluetongue virus, is conserved among the 24 bluetongue virus serotypes. The gene encoding VP7 of serotype 4 was expressed in Escherichia coli. A semi-synthetic chicken antibody library was screened with the resulting protein. Six single-chain antibody fragments (scFvs) were isolated. Immune sera blocked the binding of four of the six scFvs in enzyme-linked immunosorbent assays. These scFvs recognised recombinant VP7 coated directly onto a plastic surface. Their behaviour therefore differs from that of scFv F10 which was selected earlier on directly immobilised bluetongue virus and which binds to VP7 only when it is captured by an immobilised immunoglobulin directed against bluetongue virus.     

古尔图病毒重组截短糖蛋白基因的表达及抗体的制备

目的:原核表达古尔图病毒(Guertu virus,GTV)糖蛋白截短片段(Gn、Gn1、Gn2、Gn3、Gc1和Gc2),分别纯化Gn-His、Gc1-His和Gc2-His重组蛋白并制备其多克隆抗体。方法:采用RT-PCR的方法分别扩增得到GTV DXM毒株截短糖蛋白Gn、Gn1、Gn2、Gn3、Gc1和Gc2基因片段,并将其构建到原核表达载体pET-32a(+)中,继而转化到E.coli BL21(DE3)中进行诱导表达,SDS-PAGE分析蛋白质大小。经镍柱亲和层析纯化Gn-His、Gc1-His和Gc2-His重组蛋白,用GTV阳性羊血清通过Western blot法检测重组蛋白的抗原性。用纯化的蛋白质分别免疫新西兰白兔制备抗血清,ELISA法检测血清效价。将构建的真核表达载体pcDNA3.1-Gn和pcDNA3.1-Gc1/Gc2转染至哺乳动物Vero细胞,并用间接免疫荧光法评估前述制备的兔多克隆抗体的结合活性。最后用Western blot法检测血清与重组蛋白的特异性反应能力。结果:双酶切鉴定和测序结果表明pET-32a-Gn、pET-32a-Gn1/Gn2/Gn3、pET-32a-Gc1/Gc2、pcDNA3.1-Gn和pcDNA3.1-Gc1/Gc2重组表达载体构建正确,重组表达蛋白Gn-His、Gn1/Gn2/Gn3-His、Gc1/Gc2-His相对分子质量(Mr)大小分别约为63.4×103、37.1×103、31.9×103、30.8×103、40×103和54.4×103。重组表达蛋白能够被GTV阳性羊血清所识别;获得的抗GTV Gn、Gc1和Gc2兔多克隆抗体效价分别为1∶409600、1∶204800和1∶6400。间接免疫荧光检测和Western blot结果表明制备的多克隆抗体能够与真核表达产物或重组蛋白发生特异性反应。结论:重组GTV糖蛋白Gn-His、Gc1-His和Gc2-His得到了高效表达和纯化,具有较好的免疫性。制备的多克隆抗体效价高,特异性好。本研究结果为进一步开展GTV糖蛋白生物学功能及其检测方法和疫苗研究提供参考资料。     

Construction and characterization of a novel recombinant single-chain variable fragment antibody against Western equine encephalitis virus

A novel recombinant single-chain fragment variable (scFv) antibody against Western equine encephalitis virus (WEE) was constructed and characterized. Using antibody phage display technology, a scFv was generated from the WEE specific hybridoma, 10B5 E7E2. The scFv was fused to a human heavy chain IgG1 constant region (CH1-CH3) and contained an intact 6 His tag and enterokinase recognition site (RS10B5huFc). The RS10B5huFc antibody was expressed in E. coli and purified by affinity chromatography as a 70-kDa protein. The RS10B5huFc antibody was functional in binding to WEE antigen in indirect enzyme-linked immunosorbent assays (ELISAs). Furthermore, the RS10B5huFc antibody was purified in proper conformation and formed multimers. The addition of the human heavy chain to the scFv replaced effector functions of the mouse antibody. The Fc domain was capable of binding to protein G and human complement. The above properties of the RS10B5huFc antibody make it an excellent candidate for immunodetection and immunotherapy studies.     

Production and characterization of an anti-idiotypic antibody specific for a monoclonal antibody to glycoprotein D of herpes simplex virus

A monoclonal antibody specific for glycoprotein D (gD) of herpes simplex virus type 1 (HSV-1) was used to prepare an anti-idiotypic antibody in rabbits. After removal of antibody reactivity to constant region determinants by absorption with polyclonal mouse immunoglobulins and a monoclonal antibody of the same subclass as the anti-gD monoclonal, the anti-idiotypic (anti-id) antibody reacted specifically with anti-gD. Using an ELISA inhibition assay with immunoaffinity-purified gD, the anti-id D reagent inhibited the binding of anti-gD to gD, suggesting that anti-id D mimics an epitope of gD by binding the antigen-combining site of anti-gD. Immunization of mice with anti-id D could prime splenocytes in vivo to proliferate in response to HSV antigen stimulation in vitro. The possibility that anti-id D could act similarly to gD and stimulate an immune response to HSV when administered in vivo is discussed.     

Characterization of rabies virus glycoprotein expressed by recombinant baculovirus.

A cDNA of the glycoprotein (G protein) gene of rabies virus Nishigahara strain was cloned and inserted into a baculovirus genome under the control of the polyhedrin promoter. Infection of Spodoptera frugiperda cells with this recombinant virus produced a large quantity of new protein instead of the parental polyhedrin protein. By immunofluorescent and immunoblotting analyses, the recombinant protein was antigenically similar to the authentic G protein. Its molecular mass estimated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, however, was slightly smaller than that of the authentic one, and this observation was suggested to be due to the difference in glycosylation level between the two G proteins. The recombinant G protein expressed on the cell surface of the insect cells showed a fusion activity at low pH. The fusion activity was inhibited by antiserum against either whole virions or G protein of rabies virus.     

Characterization of haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed by a recombinant baculovirus

A recombinant baculovirus containing a cDNA which encodes haemagglutinin-neuraminidase (HN) of Newcastle disease virus (NDV) was constructed. Spodoptera frugiperda cells infected with this recombinant virus produced a large amount of HN glycoprotein similar to the authentic HN in size. The recombinant HN glycoprotein was localized on the surface of the infected cells and conserved its haemadsorption and neuraminidase activities. The antigenic properties of the recombinant HN glycoprotein seemed to be slightly different from the authentic one, as judging by the reactivity with a panel of monoclonal antibodies specific to the antigenic sites responsible for neutralization of viral infectivity. Chickens inoculated with the cells infected with the recombinant virus developed haemagglutination-inhibition and virus neutralization antibodies, and were completely protected from the NDV challenge.     

Differentiation of Candida albicans and Candida dubliniensis by using recombinant human antibody single-chain variable fragments specific for hyphae

To identify antigens specific for the filamentous form of Candida albicans, a combinatorial phage display library expressing human immunoglobulin heavy and light chain variable regions was used to select phage clones capable of binding to the surfaces of viable C. albicans filaments. Eight distinct phage clones that bound specifically to filament surface antigens not expressed on blastoconidia were identified. Single-chain antibody variable fragments (scFv) derived from two of these phage clones (scFv5 and scFv12) were characterized in detail. Filament-specific antigen expression was detected by an indirect immunofluorescence assay. ScFv5 reacted with C. dubliniensis filaments, while scFv12 did not. Neither scFv reacted with C. glabrata, C. parapsilosis, C. rugosa, C. tropicalis, or Saccharomyces cerevisiae grown under conditions that stimulated filament formation in C. albicans and C. dubliniensis. Epitope detection by the two scFv was sensitive to proteinase K treatment but not to periodate treatment, indicating that the cognate epitopes were composed of protein. The antigens reactive with scFv5 and scFv12 were extractable from the cell surface with Zymolyase, but not with sodium dodecyl sulfate (SDS) and 2-mercaptoethanol, and migrated as polydisperse, high-molecular-weight bands on SDS-polyacrylamide gel electrophoresis gels. The epitopes were detected on clinical specimens obtained from infants with thrush and urinary candidiasis without passage of the organisms on laboratory media, confirming epitope expression in human infection. The availability of a monoclonal immunologic reagent that recognizes filaments from both C. albicans and C. dubliniensis and another specific only to C. albicans adds to the repertoire of potential diagnostic reagents for differentiation between these closely related species.     

Expression of the bovine leukemia virus envelope glycoprotein (gp51) by recombinant baculovirus and its use in an enzyme-linked immunosorbent assay

The gene encoding the major envelope glycoprotein (gp51) with its signal sequence, represented by an additional NH2-terminal 33-residue amino acid sequence of bovine leukemia virus (BLV), was inserted into a baculovirus transfer vector. A recombinant virus expressing a secreted gp51 protein in insect cells was isolated. The recombinant gp51 expressed was characterized by using an anti-BLV monoclonal antibody by both Western blotting analysis and enzyme-linked immunosorbent assay (ELISA). The secreted gp51 was used as an antigen, and an ELISA with recombinant gp51 (rgp51) was developed for the detection of BLV antibodies. This new procedure was compared with a previous ELISA method for the detection of BLV antibodies and an agar gel immunodiffusion test performed with an unpurified BLV antigen preparation. The comparative testing of field samples showed that the ELISA with rgp51 is more specific and also suitable for the testing of pooled sera.     

Molecular profile of a human monoclonal antibody Fab fragment specific for Epstein-Barr virus gp350/220 antigen

Experimental evidence indicates Epstein Barr virus (EBV) envelope glycoprotein gp350/220 elicits a potent virus neutralizing response in the infected human host that may play an important role in restricting viral pathogenesis. In this study, we report the molecular cloning in combinatorial phage display vectors, of the IgG1 repertoire of an individual naturally infected with EBV, and describe the recovery and characterization of a monoclonal antibody recognizing gp350/220. A detailed understanding of the human antibody response in EBV infection will identify antibodies of potential use in anti-viral prophylaxis and will advance the production of more effective vaccine candidates.     

Site-directed cytotoxic antibody against the C-terminal segment of the surface glycoprotein gp90 of avian reticuloendotheliosis virus

The major mature env-gene products of avian reticuloendotheliosis-associated virus (REV-A) are the surface glycoprotein (gp90) and the transmembrane protein (gp20). We have previously reported that gp90 was detected in the REV-A virus by Western blot analysis as well as in the REV-A-infected cells by radioimmunoprecipitation with antibodies raised in rabbits against the gp90 C-terminal tridecapeptide which was predicted from the nucleotide sequence (Wilhemsen et al., J. Virol., 52, 172, 1984). We have now shown that this antibody detected antigens on the REV-A-infected cells by fluorescence-activated cell sorter (FACS) analysis, and conferred specific cytotoxic effects on the infected cells in the presence of rabbit complement using the chromium release assay. These results clearly indicate that the C-terminal epitope of gp90 is situated on the surface of the REV-A-infected cells and accessible to site-directed antibodies which cause cytotoxicity by activating the complement system. The possible in vivo roles of this antibody are discussed.     

Aβ单链抗体基因腺相关病毒的包装和纯化

目的 包装和纯化携带Aβ单链抗体基因的腺相关病毒，为阿尔茨海默病的基因治疗创造条件。 方法 用Lipofectamine 2000将pSNAV2.0-Abeta-scFv质粒转染BHK-21细胞并用G418筛选稳定细胞系。培养稳定细胞系用辅助病毒HSV1-rc/ UL2感染包装携带Aβ单链抗体基因的腺相关病毒。用氯仿-PEG/NaCl-氯仿法和离子交换层析法纯化重组腺相关病毒，SDS-PAGE和PCR方法检测纯化的病毒。用地高辛标记探针测定重组腺相关病毒的物理滴度。利用水迷宫测试重组病毒对转基因阿尔茨海默病小鼠模型的治疗效果。结果 带Aβ单链抗体基因的腺相关病毒的纯度为98%，物理滴度为1×1012vg/ml。经过治疗的小鼠模型潜伏期明显缩短。 结论 利用HSV1系统成功包装和纯化了携带Aβ单链抗体基因的腺相关病毒，动物实验表明对阿尔茨海默病具有治疗作用。     

The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries

Antibody phage display technology was used to identify human monoclonal antibodies that neutralize rabies virus (RV). A phage repertoire was constructed using antibody genes harvested from the blood of vaccinated donors. Selections using this repertoire and three different antigen formats of the RV glycoprotein (gp) resulted in the identification of 147 unique antibody fragments specific for the RV gp. Analysis of the DNA sequences of these antibodies demonstrated a large variation in the heavy- and light-chain germ-line gene usage, suggesting that a broad antibody repertoire was selected. The single-chain variable fragment (scFv) antibodies were tested in vitro for RV neutralization, resulting in 39 specificities that neutralize the virus. Of the scFv clones, 21 were converted into full-length human IgG(1) format. Analysis of viral escape variants and binding competition experiments indicated that the majority of the neutralizing antibodies are directed against antigenic site III of the RV gp. The obtained specificities expand the set of human anti-RV antibodies eligible for inclusion in an antibody cocktail aimed for use in rabies post-exposure prophylaxis.     

Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus.

Sequence variation in the gp116 component of cytomegalovirus envelope glycoprotein B was examined in 11 clinical strains and compared with variation in gp55. The peptide variation in gp116 was found to be strongly clustered at codons 27-67, 440-460, and to a lesser extent at codons 181-194, 311-317, and 387-397. Strains adopted one of three to four peptide configurations at these loci, usually consistent with their gp55 sequence configuration. Two instances were observed of a sequence variation arising from recombination within gB. The limited, largely group-specific nature of variation in both gp116 and gp55 facilitates functional and immunologic analyses.     

Characterization and gene cloning of monoclonal antibody specific for the hepatitis B virus X protein

The hepatis B virus X protein (HBx) has been thought to be implicated in the development of hepatocellular carcinoma. Although many functions of HBx have been reported, it is not clear which of HBx functions is important in hepatocellular carcinogenesis. To study HBx function, we produced a monoclonal anti-HBx Ab secreted by hybridoma cell clone H7 and mapped its epitope to a region of HBx between amino acids 29 and 48 by Western blot with truncated forms of HBx and by enzyme-linked immunoadsorbent assay (ELISA) with synthetic HBx peptides. The variable regions of H7 anti-HBx Ab were cloned by polymerase chain reaction using the degenerate-primers and by the 5' rapid amplification-cDNA end method. The sequence analyses revealed that the variable gene segments of the heavy and light chains are the members of mouse heavy chain variable gene 1 family and kappa light chain variable gene 2 family, respectively. In addition, J(H)2 or Jkappa4 gene segment at the end of the heavy-chain or light-chain variable region and DSP2.x gene segment in the CDR 3 of heavy chain were identified.     

Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII,and gIII as a PR vaccine for pigs

Summary Pigs vaccinated twice intramuscularly with a highly attenuated strain of vaccinia virus (NYVAC) containing gene inserts for pseudorabies virus (PRV) glycoproteins gp50, gII, and gIII produced neutralizing antibodies for PRV and were less clinically affected than were nonvaccinated pigs following oronasal exposure to virulent PRV. Also, following oronasal exposure to virulent PRV the duration of virulent virus shedding by pigs that had been vaccinated intramuscularly with the recombinant virus was statistically less (p<0.05) than that of nonvaccinated pigs and like that of pigs vaccinated twice intramuscularly with inactivated PR vaccine. Intramuscular vaccination with the recombinant virus was compatible with the most commonly used differential diagnostic tests, namely those based on PRV glycoproteins gX and gI. Serum antibodies for these glycoproteins were absent from the sera of all pigs before and after vaccination with recombinant virus; whereas, they were present in the sera of all of the same pigs after they were exposed to virulent PRV. In contrast to the effectiveness of the recombinant virus administered intramuscularly, neither serum antibody nor clinical protection against PRV was detected when aliquots of the same recombinant virus preparation were administered either orally or intranasally. The latter finding suggests that recombinant virus replicates poorly, if at all, at these sites. If so, the dissemination of recombinant virus from vaccinated pigs to nonvaccinated pigs or other animals in contact seems unlikely.